Nikhil Prasad Fact checked by:Thailand Medical News Team Jan 27, 2025 1 day, 11 hours, 29 minutes ago
Medical News: A Breakthrough in Antiviral Research
Researchers from the Smorodintsev Research Institute of Influenza, under the Ministry of Health of the Russian Federation, have made strides in exploring the antiviral potential of mRNA technology. In their latest study, scientists evaluated how exogenous mRNA encoding human myxovirus resistance protein A (MxA) might suppress viral infections. This
Medical News report dives into their findings, which may offer hope for developing advanced antiviral treatments.
The Antiviral Properties of mRNA Encoding the Human MxA Protein
Understanding MxA and Its Potential
MxA is a powerful protein naturally produced in human cells exposed to type I and III interferons, molecules critical for the immune response. This protein has shown the ability to inhibit a range of viruses, including influenza A, by disrupting the virus's replication processes.
Building on the recent success of mRNA-based technologies, such as COVID-19 vaccines, the research team investigated whether exogenous mRNA could be used to produce functional MxA protein within cells. Unlike traditional treatments, mRNA-based therapies introduce a genetic template that cells use to manufacture a therapeutic protein.
The Methodology of the Study
The study synthesized exogenous mRNA encoding MxA using advanced in vitro transcription techniques. The resulting mRNA included essential elements such as modified pseudouridine nucleotides and protective cap structures to ensure stability and efficient translation in cells. Control experiments were conducted with mRNA encoding green fluorescent protein (GFP) to assess non-specific effects.
Cell lines, including A549 and MDCK cells, were transfected with MxA-mRNA, and the production of MxA protein was evaluated through techniques like ELISA and immunofluorescence staining. The antiviral effects of MxA-mRNA were then tested against a variety of RNA viruses, including influenza A and B, respiratory syncytial virus (RSV), and SARS-CoV-2.
Promising Results with Influenza Viruses
One of the most significant findings of the study was MxA-mRNA's ability to reduce influenza virus levels by 10-80 times in cell cultures. This reduction was observed for both influenza A and B strains. Notably, the control GFP-mRNA did not exhibit similar antiviral activity. The specific effect of MxA-mRNA highlights its potential as a targeted antiviral therapy.
While these results are encouraging, researchers noted that the antiviral effect was less pronounced than in previous studies using cells engineered to stably produce MxA protein. This discrepancy is likely due to the temporary nature of mRNA-based protein production and the ability of some influenza strains to adapt and evade MxA's inhibitory effects.
Limited Effectiveness Against Other Viruses
The study also tested MxA-mRNA's activity against other RNA viruses, including RSV and SARS-CoV-2.
Unfortunately, the mRNA treatment did not significantly suppress the replication of these viruses. Researchers suggest this could be due to the unique genetic makeup of these viruses or their ability to resist MxA's actions. Further research is needed to explore ways to enhance the effectiveness of MxA-mRNA against a broader range of pathogens.
Challenges with Immunogenicity
One of the hurdles in developing mRNA-based therapies is immunogenicity, which refers to the immune system's response to foreign substances. The study found that both MxA-mRNA and GFP-mRNA triggered an increase in interferon production, a key part of the immune response. While this immune activation may help fight infections, it can also reduce the efficiency of protein production and lead to unwanted inflammation. Balancing immunogenicity with therapeutic efficacy remains a critical challenge.
Implications and Future Directions
The findings of this study demonstrate that mRNAs encoding natural antiviral proteins like MxA have great therapeutic potential. By harnessing mRNA technology, scientists can produce proteins with high specificity and minimal risk of genetic integration. However, the study also highlights the limitations of current mRNA platforms, particularly in overcoming viral resistance and managing immune responses.
In the future, researchers aim to refine the design of exogenous mRNAs to reduce their immunogenicity and enhance their antiviral properties. Advancements in delivery systems and mRNA modifications may help unlock the full potential of this promising technology.
Conclusion
This study provides a valuable proof of concept for using mRNA-based therapies to combat viral infections. While the results show promise for treating influenza viruses, challenges remain in extending these benefits to other pathogens. The researchers emphasized the need for continued innovation in mRNA design and delivery to overcome these obstacles.
The study findings were published in the peer-reviewed journal: Microbiology
Research.
https://www.mdpi.com/2036-7481/16/2/32
For the latest on Antivirals, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/protacs-new-antiviral-approach-to-combatting-viruses
https://www.thailandmedical.news/news/u-s-nih-discovers-new-potential-antivirals-against-sars-cov-2-involving-p97-inhibitors
https://www.thailandmedical.news/news/korean-study-finds-that-hovenia-dulcis-honey-has-antiviral-properties-against-influenza-a-viruses
https://www.thailandmedical.news/news/french-study-finds-that-a-phytochemical-from-st-john-s-wort-shows-promise-as-a-broad-spectrum-antiviral-against-coronaviruses
https://www.thailandmedical.news/news/natural-indoles-from-the-gardneria-multiflora-makino-plant-emerging-as-potential-antiviral-agents-against-hiv-and-hcv
Share
Tweet
Share
